Artificial intelligence has moved from pilot projects to a central role in many life sciences strategies. What began as a set ...
When David Fajgenbaum was in medical school, he was diagnosed with an incurable illness called Castleman disease. He was 25 years old when doctors told him “there’s nothing we can do,” and a priest ...
In a recently accepted manuscript titled “Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data”, scientists from Insilico ...
Overview: The global Artificial Intelligence (AI) in drug discovery market is projected to grow at a rate of 25-30% over the ...
How innovative technologies like AI and gene editing are advancing rare disease drug discovery and development.
The collaboration will combine Syngene’s preclinical development expertise with VivaMed's AI-generated therapeutic hypotheses.
The study in brief: Cancer research//Basic research//Peer review publication//Researcher-initiated study//Computer simulation//Animal study//In vitro/In vivo//In ...
Artificial intelligence is emerging as a powerful tool for improving the diagnosis, phenotyping, and treatment of inflammatory skin diseases such as alopecia.
IAN Alpha Fund, the 2nd in the series of IAN Group’s VC funds, along with Speciale Invest, has co-led a ₹70 crore Series A funding round in Peptris, a Bengaluru-based AI-powered drug discovery company ...